论文部分内容阅读
本研究观察了本室制备的抗腺癌肿瘤疫苗的抑瘤效果.将C57小鼠随机分为实验组及对照组.实验组即抗腺癌肿瘤疫苗+环磷酰胺(Cyclo)组,其又根据抗腺癌肿瘤疫苗的不同剂量分为5组(0.1μg、0.5μg a、0.5μg b、15μg);对照组:0.9%NaCl a组,0.9%NaCl b组,BCG组及单纯Cyclo组.实验组自-57天起每间隔2周于鼠尾根部双侧皮下肿瘤疫苗免疫1次,此外在-45天给予实验组鼠腹腔注射Cyclo 3 mg/只;与此同时NaCl组相应给予0.9%NaCl注射液;BCG组除在-57天于尾根部双侧皮下注射BCG 0.25mg/只外,在接种Lewis肺癌细胞后,待肿瘤长径至0.8cm时,于肿瘤基底部注射BCG,剂量同前;单纯Cyclo组于-57天、-10天给予C57小鼠腹腔注射Cyclo 3mg/只.各组C57小鼠均于0天接
This study observed the anti-tumor effect of anti-cancer tumor vaccine prepared in our laboratory. C57 mice were randomly divided into experimental group and control group. The experimental group was anti-adenocarcinoma tumor vaccine + cyclophosphamide (Cyclo) group. According to different doses of anti-adenocarcinoma tumor vaccines, they were divided into 5 groups (0.1 μg, 0.5 μg a, 0.5 μg b, 15 μg); Control group: 0.9% NaCl a group, 0.9% NaCl b group, BCG group and Cyclo alone group. The experimental group was immunized once every two weeks from the -57th day to two subcutaneous tumors of the rat tail root. In addition, the mice in the experimental group were given an intraperitoneal injection of Cyclo 3 mg/only at -45 days; meanwhile, the NaCl group was given 0.9% accordingly. In the NaCl injection group, the BCG group was injected BCG 0.25 mg/kg subcutaneously on both sides of the tail root at -57 days. After inoculation of Lewis lung cancer cells, the BCG was injected into the base of the tumor when the tumor length reached 0.8 cm. Before; Cyclo group was given C57 mice intraperitoneally with Cyclo 3mg/day at -57 days and -10 days. Each group of C57 mice were received on day 0.